Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
morphine	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Fever,	O
nausea,	O
flank	O
pain,	O
nephrostomy	O
tube	O
fell	O
out	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
nephrostomy	O
tube	O
replacement	O
in	O
interventional	O
radiology	O
History	O
of	O
Present	O
Illness:	O
Ms.	O
___	O
is	O
a	O
___	O
year-old	O
woman	O
with	O
past	O
medical	O
history	O
of	O
urothelial	O
carcinoma	O
with	O
sarcomatoid	O
features	O
(likely	O
representing	O
two	O
separate	O
primary	O
malignanices	O
-	O
high	O
grade	O
sarcoma,	O
high-grade	O
poorly-differentiated	O
urothelial	O
carcinoma	O
with	O
sarcomatoid	O
features)	O
diagnosed	O
___	O
with	O
mets	O
to	O
the	O
vaginal	O
wall,	O
right	O
adnexa,	O
retroperitoneal	O
lymph	O
nodes,	O
and	O
right	O
lower	O
lobe	O
of	O
the	O
lung.	O
Her	O
malignancy	O
has	O
been	O
complicated	O
by	O
left-sided	O
hydronephrosis	O
which	O
was	O
interevened	O
upon	O
___	O
with	O
a	O
left	O
percutaneous	O
nephrostomy.	O
She	O
has	O
been	O
started	O
on	O
treatment	O
with	O
carboplatin/gemcitabine	O
on	O
___	O
(C1D1).	O
Per	O
OMR	O
Oncology	O
notes:	O
she	O
was	O
admitted	O
to	O
___	O
on	O
___	O
for	O
UTI.	B-Urinary_tract_infection
Presenting	O
symptoms	O
were	O
fever,	O
nausea,	O
vomiting,	O
and	O
blood	O
from	O
her	O
nephrostomy.	O
Culture	O
positive	O
for	O
enterococcus,	O
strep	O
species,	O
and	O
gram-negative	O
rods.	O
She	O
was	O
treated	O
with	O
Vancomycin,	O
Zosyn,	O
Ceftriaxone,	O
and	O
Ciprofloxacin	O
which	O
this	O
was	O
narrowed	O
to	O
Ceftriaxone	O
alone,	O
and	O
transitioned	O
to	O
amoxicillin	O
x	O
7	O
days	O
on	O
discharge.	O
___	O
she	O
presented	O
to	O
___	O
with	O
fevers	O
and	O
L	O
sided	O
flank	O
pain	O
after	O
her	O
left	O
nephrostomy	O
tube	O
fell	O
out.	O
She	O
was	O
originally	O
going	O
to	O
have	O
non-emergent	O
placement	O
of	O
a	O
nephrostomy	O
tube,	O
however,	O
she	O
developed	O
nausea,	O
fever,	O
and	O
left	O
flank	O
pain.	O
She	O
was	O
started	O
on	O
ceftriaxone	O
and	O
transferred	O
to	O
___.	O
Upon	O
arrival	O
to	O
___	O
she	O
continues	O
to	O
have	O
nausea	O
and	O
malaise.	O
Past	O
Medical	O
History:	O
Oncologic	O
History:	O
-	O
___:	O
mild	O
abdominal	O
pain,	O
with	O
CT	O
chest/abdomen/pelvis	O
showing	O
bilateral	O
pulmonary	O
nodules	O
(largest	O
3	O
cm),	O
a	O
large	O
6.3	O
cm	O
infrarenal	O
AAA,	O
and	O
L-sided	O
hydroureteronephrosis	O
possible	O
due	O
to	O
significant	O
mass	O
effect	O
on	O
the	O
ureter	O
(secondary	O
to	O
large	O
aneurysm,	O
along	O
with	O
non-specific	O
R	O
hepatic	O
hypodensity	O
and	O
colonic	O
diverticulosis).	O
Subsequent	O
duplex	O
ultrasound	O
of	O
the	O
abdomen	O
demonstrated	O
no	O
evidence	O
of	O
a	O
AAA,	O
but	O
did	O
show	O
a	O
heterogeneous	O
mass	O
that	O
encircled	O
the	O
abdominal	O
aorta	O
from	O
below	O
the	O
level	O
of	O
the	O
renal	O
arteries	O
and	O
distal	O
to	O
the	O
aortic	O
bifurcation.	O
-	O
___:	O
PET-CT	O
shows	O
FDG	O
avidity	O
in	O
a	O
2.4	O
cm	O
R	O
adnexal	O
mass,	O
suspicious	O
for	O
ovarian	O
malignancy,	O
as	O
well	O
FDG-avid	O
soft	O
tissue	O
along	O
the	O
posterior	O
bladder	O
wall	O
(suspicious	O
for	O
serosal	O
implants),	O
and	O
an	O
FDG-avid	O
RP	O
mass.	O
Additionally,	O
there	O
was	O
a	O
3.1	O
cm	O
FDG-avid	O
RLL	O
lung	O
mass	O
and	O
stable	O
bilateral	O
hydronephrosis.	O
MRI	O
of	O
the	O
pelvis	O
showed	O
a	O
3.7	O
x	O
3.7	O
cm	O
mass	O
in	O
the	O
R	O
adnexa,	O
suspicious	O
for	O
metastatic	O
disease,	O
as	O
well	O
as	O
asymmetric	O
thickening	O
on	O
the	O
posterior	O
aspect	O
of	O
the	O
bladder	O
wall.	O
FNA	O
of	O
the	O
RP	O
mass	O
was	O
positive	O
for	O
malignant	O
cells.	O
-	O
___:	O
Dr.	O
___	O
cystoscopy	O
with	O
transurethral	O
biopsy	O
of	O
the	O
bladder	O
mass,	O
which	O
showed	O
a	O
high-grade	O
urothelial	O
carcinoma	O
that	O
was	O
poorly	O
differentiated,	O
along	O
with	O
rare	O
sarcomatoid	O
features.	O
Vaginal	O
biopsy	O
showed	O
infiltrating,	O
poorly-differentiated	O
carcinoma,	O
consistent	O
with	O
high-grade	O
urothelial	O
carcinoma	O
invading	O
the	O
vaginal	O
muscular	O
wall.	O
-	O
___:	O
L-sided	O
percutaneous	O
nephrostomy	O
tube	O
placed.	O
-	O
___:	O
UTI,	B-Urinary_tract_infection
treated	O
with	O
ciprofloxacin	O
-	O
___:	O
CT	O
abdomen/pelvis	O
demonstrates	O
increased	O
size	O
of	O
retroperitoneal	O
mass,	O
along	O
with	O
right	O
middle	O
lobe	O
lung	O
nodule	O
concerning	O
for	O
malignancy.	O
Discussion	O
of	O
her	O
case	O
at	O
multi-disciplinary	O
GU	O
Oncology	O
Tumor	O
Board	O
yields	O
consensus	O
that	O
this	O
represents	O
two	O
separate	O
primary	O
malignancies.	O
-	O
___:	O
C1D1	O
of	O
palliative	O
carboplatin/gemcitabine.	O
-	O
___:	O
Admitted	O
to	O
___	O
with	O
UTI,	B-Urinary_tract_infection
treated	O
with	O
Vancomycin/Zosyn/Ceftriaxone/Ciprofloxacin,	O
narrowed	O
to	O
Ceftriaxone	O
and	O
discharged	O
to	O
complete	O
a	O
course	O
of	O
amoxicillin.	O
Pegfilgrastim	O
6	O
mg	O
SC	O
administered.	O
-	O
___:	O
C1D8	O
of	O
gemcitabine	O
held	O
because	O
of	O
leukocytosis.	O
Past	O
Medical	O
History:	O
-	O
Urothelial	O
carcinoma	O
with	O
sarcomatoid	O
features,	O
as	O
above	O
-	O
UTI	B-Urinary_tract_infection
-	O
Hypertension	O
-	O
Anemia	O
-	O
Seizure	B-Seizures
disorder	O
-	O
Atypical	O
chest	O
pain	O
-	O
Depression	O
-	O
Fibromyalgia	O
-	O
GERD	O
-	O
Gastric	O
ulcer	O
-	O
Bowel	B-Faecal_incontinence
incontinence	B-Faecal_incontinence
-	O
Lower	O
back	O
pain	O
-	O
Lung	O
nodule	O
-	O
Osteopenia	O
Social	O
History:	O
___	O
Family	O
History:	O
Per	O
previous	O
notes,	O
The	O
patient	O
has	O
three	O
sisters	O
who	O
are	O
still	O
alive	O
and	O
well.	O
They	O
have	O
no	O
history	O
of	O
malignancy.	O
The	O
patient's	O
father	O
and	O
mother	O
passed	O
away,	O
not	O
related	O
to	O
malignancy.	O
The	O
patient	O
has	O
two	O
adopted	O
children.	O
Physical	O
Exam:	O
PHYSICAL	O
EXAM:	O
Vitals:	O
98	O
150/62	O
71	O
18	O
95%RA	O
GEN:	O
alert,	O
oriented	B-Delirium
and	O
appropriate.	O
NAD	O
HEENT:	O
NCAT,	O
sclerae	O
non-icteric,	O
o/p	O
clear,	O
MMM.	O
Lymph	O
nodes:	O
No	O
cervical	O
LAD.	O
CV:	O
S1S2,	O
reg	O
rate	O
and	O
rhythm,	O
no	O
murmurs,	O
rubs	O
or	O
gallops.	O
RESP:	O
Good	O
air	O
movement	O
bilaterally,	O
no	O
rhonchi	O
or	O
wheezing.	O
GI:	O
Soft,	O
nontender,	O
non-distended,	O
+	O
bowel	O
sounds	O
Back:	O
nephrostomy	O
C/D/I,	O
draining	O
clear	O
pale	O
yellow	O
urine.	O
no	O
CVA	O
tenderness	O
EXTR:	O
No	O
lower	O
leg	O
edema,	O
no	O
clubbing	O
or	O
cyanosis	O
DERM:	O
No	O
active	O
rash.	O
Neuro:	O
Oriented	B-Delirium
and	O
appropriate,	O
moving	O
all	O
extremities,	O
no	O
gross	O
deficits.	O
PSYCH:	O
Appropriate	O
and	O
calm.	O
Pertinent	O
Results:	O
___	O
08:15AM	O
BLOOD	O
WBC-6.1	O
RBC-3.23*	O
Hgb-9.2*	O
Hct-27.9*	O
MCV-87	O
MCH-28.4	O
MCHC-32.8	O
RDW-15.4	O
Plt	O
___	O
___	O
01:15AM	O
BLOOD	O
WBC-16.1*#	O
RBC-3.59*	O
Hgb-10.2*	O
Hct-30.7*	O
MCV-86	O
MCH-28.5	O
MCHC-33.3	O
RDW-15.5	O
Plt	O
___	O
___	O
08:15AM	O
BLOOD	O
Glucose-81	O
UreaN-10	O
Creat-1.6*	O
Na-145	O
K-3.3	O
Cl-111*	O
HCO3-24	O
AnGap-13	O
___	O
01:15AM	O
BLOOD	O
Glucose-112*	O
UreaN-18	O
Creat-1.5*	O
Na-136	O
K-4.4	O
Cl-104	O
HCO3-20*	O
AnGap-16	O
CT	O
Abd	O
___:	O
IMPRESSION:	O
1.	O
The	O
left	O
nephrostomy	O
tube	O
is	O
no	O
longer	O
present	O
and	O
there	O
is	O
new	O
moderate	O
hydronephrosis	O
and	O
hydroureter	O
on	O
the	O
left.	O
2.	O
Unchanged	O
right	O
middle	O
lobe	O
lung	O
nodule.	O
Concerning	O
for	O
malignancy.	O
3.	O
Retroperitoneal	O
mass	O
has	O
decreased	O
in	O
size	O
compared	O
to	O
the	O
prior	O
study	O
of	O
___,	O
consistent	O
with	O
shrinkage	O
of	O
the	O
known	O
sarcoma.	O
4.	O
Unchanged	O
thickening	O
of	O
the	O
posterior	O
wall	O
of	O
the	O
bladder	O
consistent	O
with	O
known	O
malignancy	O
Outside	O
records	O
review:	O
___	O
___	O
admitted	O
for	O
chills,	O
nausea,	O
L	O
abd/flank	O
pain.	O
treated	O
with	O
antibiotics:	O
vanc/zosyn/ceftriaxone	O
in	O
ED,	O
ceftriaxone	O
during	O
hospitalization,	O
discharged	O
on	O
amoxicillin	O
for	O
7	O
days.	O
urine	O
culture	O
grew	O
___	O
colonies	O
pan	O
sensitive	O
enterococcus	O
from	O
voided	O
specimen	O
and	O
<1000	O
colonies	O
nonhemolytic	O
strep	O
and	O
GNR	O
from	O
nephrostomy	O
specimen.	O
___	O
1:30	O
am	O
BLOOD	O
CULTURE	O
**FINAL	O
REPORT	O
___	O
Blood	O
Culture,	O
Routine	O
(Final	O
___:	O
PSEUDOMONAS	O
AERUGINOSA.	O
FINAL	O
SENSITIVITIES.	O
Piperacillin/Tazobactam	O
sensitivity	O
testing	O
performed	O
by	O
___	O
___.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
PSEUDOMONAS	O
AERUGINOSA	O
|	O
CEFEPIME--------------	O
16	O
I	O
CEFTAZIDIME-----------	O
=>64	O
R	O
CIPROFLOXACIN---------<=0.25	O
S	O
GENTAMICIN------------	O
2	O
S	O
MEROPENEM-------------	O
1	O
S	O
PIPERACILLIN/TAZO-----	O
I	O
TOBRAMYCIN------------	O
<=1	O
S	O
___	O
2:40	O
pm	O
URINE	O
Site:	O
KIDNEY	O
DUE	O
TO	O
LABORATORY	O
ERROR	O
,	O
SPECIMEN	O
WAS	O
NOT	O
PLANTED	O
QUANTITATIVELY.	O
**FINAL	O
REPORT	O
___	O
FLUID	O
CULTURE	O
(Final	O
___:	O
PSEUDOMONAS	O
AERUGINOSA.	O
SPARSE	O
GROWTH.	O
Piperacillin/Tazobactam	O
sensitivity	O
testing	O
performed	O
by	O
___	O
___.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
PSEUDOMONAS	O
AERUGINOSA	O
|	O
CEFEPIME--------------	O
16	O
I	O
CEFTAZIDIME-----------	O
=>___	O
R	O
CIPROFLOXACIN---------<=0.25	O
S	O
GENTAMICIN------------	O
2	O
S	O
MEROPENEM-------------	O
1	O
S	O
PIPERACILLIN/TAZO-----	O
I	O
TOBRAMYCIN------------	O
<=1	O
S	O
Brief	O
Hospital	O
Course:	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
further	O
treatment	O
of	O
her	O
complicated	O
pyelonephritis.	B-Urinary_tract_infection
She	O
was	O
initially	O
started	O
on	O
Zosyn.	O
She	O
had	O
replacement	O
of	O
her	O
percutaneous	O
nephrostomy	O
tube	O
in	O
interventional	O
radiology.	O
The	O
tube	O
continued	O
to	O
drain	O
cloudy	O
urine	O
for	O
the	O
first	O
day	O
after	O
which	O
it	O
cleared	O
up.	O
during	O
this	O
period	O
she	O
also	O
defervesced.	O
despite	O
clinical	O
improvement,	O
urine	O
and	O
blood	O
cultures	O
showed	O
that	O
she	O
was	O
growing	O
a	O
resistant	O
Pseudomonas	O
strain.	O
Infectious	O
diseases	O
was	O
consulted	O
and	O
she	O
was	O
switched	O
to	O
meropenem.	O
she	O
was	O
continued	O
on	O
this	O
for	O
three	O
days.	O
At	O
discharge	O
she	O
was	O
switched	O
to	O
ciprofloxacin	O
to	O
continue	O
for	O
two	O
weeks.	O
she	O
feels	O
well	O
with	O
complete	O
resolution	O
of	O
her	O
fevers,	O
nausea,	O
malaise,	O
flank	O
pain.	O
During	O
the	O
hospitalization	O
she	O
had	O
some	O
diarrhea.	O
C	O
diff	O
was	O
tested	O
and	O
was	O
negative	O
and	O
the	O
diarrhea	O
was	O
attributed	O
to	O
antibiotic	O
use.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Lactulose	O
15	O
mL	O
PO	O
Q6H:PRN	O
constipation	B-Constipation
2.	O
NIFEdipine	O
CR	O
60	O
mg	O
PO	O
DAILY	O
3.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q6H:PRN	O
pain	O
4.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
30	O
mg	O
PO	O
Q12H	O
5.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
constipation	B-Constipation
6.	O
PredniSONE	O
2.5	O
mg	O
PO	O
DAILY	O
7.	O
Estrogens	O
Conjugated	O
0.625	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
8.	O
Lansoprazole	O
Oral	O
Disintegrating	O
Tab	O
30	O
mg	O
PO	O
DAILY	O
9.	O
progesterone	O
micronized	O
200	O
mg	O
Oral	O
Every	O
Other	O
Day	O
10.	O
Zolpidem	O
Tartrate	O
5	O
mg	O
PO	O
HS:PRN	O
insomnia	O
11.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
12.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
13.	O
B-12	O
Plus	O
(cyanocobalamin-cobamamide)	O
5,000-100	O
mcg	O
Sublingual	O
daily	O
14.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
Discharge	O
Medications:	O
1.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
2.	O
Estrogens	O
Conjugated	O
0.625	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
3.	O
Lansoprazole	O
Oral	O
Disintegrating	O
Tab	O
30	O
mg	O
PO	O
DAILY	O
4.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
5.	O
NIFEdipine	O
CR	O
60	O
mg	O
PO	O
DAILY	O
6.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q6H:PRN	O
pain	O
7.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
30	O
mg	O
PO	O
Q12H	O
8.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
constipation	B-Constipation
9.	O
PredniSONE	O
2.5	O
mg	O
PO	O
DAILY	O
10.	O
progesterone	O
micronized	O
200	O
mg	O
Oral	O
Every	O
Other	O
Day	O
11.	O
Zolpidem	O
Tartrate	O
5	O
mg	O
PO	O
HS:PRN	O
insomnia	O
12.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
13.	O
B-12	O
Plus	O
(cyanocobalamin-cobamamide)	O
5,000-100	O
mcg	O
Sublingual	O
daily	O
14.	O
Lactulose	O
15	O
mL	O
PO	O
Q6H:PRN	O
constipation	B-Constipation
15.	O
Ciprofloxacin	O
HCl	O
500	O
mg	O
PO	O
Q12H	O
Duration:	O
2	O
Weeks	O
RX	O
*ciprofloxacin	O
500	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
every	O
twelve	O
(12)	O
hours	O
Disp	O
#*28	O
Tablet	O
Refills:*0	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
nephrostomy	O
replacement	O
pyelonephritis	B-Urinary_tract_infection
bacteremia	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
after	O
your	O
nephrostomy	O
tube	O
fell	O
out	O
and	O
you	O
developed	O
a	O
severe	O
kidney	O
infection	O
which	O
then	O
spread	O
to	O
your	O
bloodstream.	O
You	O
had	O
the	O
nephrostomy	O
tube	O
replaced	O
by	O
interventional	O
radiology	O
and	O
it	O
is	O
functioning	O
well.	O
Your	O
infection	O
appears	O
to	O
be	O
clearing	O
with	O
the	O
IV	O
antibiotics	O
you	O
received	O
and	O
you	O
will	O
be	O
discharged	O
home	O
with	O
a	O
2	O
week	O
supply	O
of	O
pill	O
antibiotics	O
to	O
help	O
your	O
body	O
make	O
sure	O
the	O
infection	O
is	O
eradicated.	O
Followup	O
Instructions:	O
___	O

